Amylin (islet amyloid polypeptide) is a recently identified pancreatic
peptide. It has been shown to affect glucose metabolism both in vitro
and in vivo. A cross sectional analysis of the effects of age on amyl
in secretion following a 75 g glucose tolerance test in a young (20-40
years), middle aged (41-60 years) and older (61-90 years) group was p
erformed. Thirty lean (BMI less than 25) non-diabetic individuals were
studied. Amylin secretion exhibited a U-shaped curve with greater sec
retion in young and old subjects than in middle aged persons. Baseline
levels were 7.2 +/- 1, 4.7 +/- 1; and 5.3 +/- 0.75 pM respectively, a
t 60 min 9.5 +/- 0.9 (y), 5.5 +/- 1 (m), 8.6 +/- 1 (o) pM; and at 120
min 10.3 +/- 2 (y), 4.4 +/- 0.5 (m), 10.9 +/- 1.5 (o) pM. Amylin produ
ction (area under the curve) was 1102 +/- 131, 619.5 +/- 79 and 1043 /- 120 pM per min respectively (P < 0.05). Amylin secretion was simila
r in both sexes. Variability in the insulin to amylin ratio for each o
f the age groups at different time points following a glucose load was
found, suggesting that insulin and amylin are not co-secreted in a fi
xed ratio. A significant association was found between both maximum am
ylin and rise in amylin (Delta) and a glucose greater than 120 mg/dl a
t 2 h. (P < 0.001, P < 0.001). This correlation of glucose and amylin
may be interpreted as suggestive of a counterregulatory role for amyli
n. However, aging is also associated with changes in glucose metabolis
m and amylin may merely be acting as a marker of impaired glucose meta
bolism.